Searle & CO. Has $172,000 Holdings in Heron Therapeutics, Inc. (NASDAQ:HRTX)

Searle & CO. increased its holdings in shares of Heron Therapeutics, Inc. (NASDAQ:HRTX) by 684.1% during the third quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 86,250 shares of the biotechnology company’s stock after acquiring an additional 75,250 shares during the quarter. Searle & CO.’s holdings in Heron Therapeutics were worth $172,000 as of its most recent filing with the SEC.

Several other hedge funds and other institutional investors have also bought and sold shares of HRTX. nVerses Capital LLC bought a new stake in shares of Heron Therapeutics in the second quarter valued at approximately $27,000. Headlands Technologies LLC acquired a new position in Heron Therapeutics in the 1st quarter valued at $30,000. Susquehanna Fundamental Investments LLC bought a new stake in shares of Heron Therapeutics during the 1st quarter valued at $32,000. HB Wealth Management LLC acquired a new stake in shares of Heron Therapeutics during the 2nd quarter worth $35,000. Finally, B. Riley Wealth Advisors Inc. bought a new position in shares of Heron Therapeutics in the second quarter worth $41,000. Institutional investors and hedge funds own 80.01% of the company’s stock.

Heron Therapeutics Price Performance

HRTX traded up $0.03 during trading on Wednesday, hitting $1.81. 519,303 shares of the stock traded hands, compared to its average volume of 2,440,008. The business has a 50 day moving average price of $1.90 and a 200 day moving average price of $2.64. Heron Therapeutics, Inc. has a twelve month low of $0.50 and a twelve month high of $3.93. The company has a market cap of $271.93 million, a price-to-earnings ratio of -2.92 and a beta of 1.80.

Heron Therapeutics (NASDAQ:HRTX) last released its quarterly earnings data on Tuesday, August 6th. The biotechnology company reported ($0.06) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.04) by ($0.02). The company had revenue of $36.02 million for the quarter, compared to analyst estimates of $35.35 million. During the same period last year, the company posted ($0.35) EPS. On average, equities research analysts predict that Heron Therapeutics, Inc. will post -0.1 earnings per share for the current year.

Wall Street Analysts Forecast Growth

Separately, Needham & Company LLC reaffirmed a “buy” rating and set a $5.00 price objective on shares of Heron Therapeutics in a research report on Wednesday, September 25th.

Heron Therapeutics Company Profile

Heron Therapeutics, Inc, a commercial-stage biotechnology company, focuses on enhancing the lives of patients by developing and commercializing therapeutic that enhances medical care. The company's product candidates utilize its proprietary Biochronomer, a drug delivery technology, which delivers therapeutic levels of a range of short-acting pharmacological agents over a period from days to weeks with a single administration.